Cost-effectiveness of recombinant zoster vaccine for adults aged ≥50 years in China

CONCLUSIONS: RZV was most likely to be cost-effective in people aged 60-69 years. A slight decrease in vaccine cost would result in RZV being cost-effective in all people aged ≥50 years.PMID:37182556 | DOI:10.1016/j.amepre.2023.05.007

Source: Herpes - May 14, 2023 Category: Infectious Diseases Authors: Minghuan Jiang Xuelin Yao Jin Peng Liuxin Feng Yue Ma Xinke Shi Yu Fang Hai Fang Source Type: research